The UK Radioligand Therapy (RLT) Market growth continues to accelerate as neuroendocrine tumour treatment evolves from somatostatin analogue therapy to precision Lutetium-177 DOTATATE radioligand therapy for progressive disease. With neuroendocrine neoplasms representing a heterogeneous and increasingly diagnosed cancer group in the UK, the demand for molecular imaging with Gallium-68 DOTATATE...